Subcutaneous octreotide in the treatment of pain in advanced cancer patients.
Octreotide is a synthetic somatostatin analogue that has been recently tested by various routes of administration as an analgesic drug for different types of pain. The authors evaluated the analgesic efficacy of a subcutaneous 200-ng bolus of octreotide on somatic and visceral pain from advanced cancer in a randomized, single-blind crossover study. The results in nine cases did not show an analgesic effect superior to that of a placebo. Pain relief was obtained in one case of postprandial visceral pain. This case is discussed in detail, and another possible clinical use for octreotide in a particular form of neoplastic pain is hypothesized.
De Conno
F
F
Palliative Care Division, National Cancer Institute, Milan, Italy.
Saita
L
L
Ripamonti
C
C
Ventafridda
V
V
D000698:Analgesia; D001859:Bone Neoplasms / Q000503:physiopathology / Q000556:secondary; D006801:Humans; D007279:Injections, Subcutaneous; D008175:Lung Neoplasms / Q000503:physiopathology; D009369:Neoplasms / Q000503:physiopathology*; D015282:Octreotide / Q000008:administration & dosage / Q000627:therapeutic use*; D010146:Pain / Q000188:drug therapy*; D010190:Pancreatic Neoplasms / Q000503:physiopathology; D016037:Single-Blind Method; D013997:Time Factors
D015282:Octreotide